An Integrated Analysis of Liver Safety Data from Orlistat Clinical Trials Obes Facts 2012;5:485–494 - DOI:10.1159/000341589 Fig. 1. Occurrence of two successive abnormal ALT measurements (60 and 120 mg orlistat combined). © 2012 S. Karger AG, Basel
An Integrated Analysis of Liver Safety Data from Orlistat Clinical Trials Obes Facts 2012;5:485–494 - DOI:10.1159/000341589 Fig. 2. Occurrence of two successive abnormal bilirubin measurements (60 and 120 mg orlistat combined). © 2012 S. Karger AG, Basel
An Integrated Analysis of Liver Safety Data from Orlistat Clinical Trials Obes Facts 2012;5:485–494 - DOI:10.1159/000341589 Fig. 3. mDISH plot between orlistat (60 and 120 mg combined) and placebo. © 2012 S. Karger AG, Basel
An Integrated Analysis of Liver Safety Data from Orlistat Clinical Trials Obes Facts 2012;5:485–494 - DOI:10.1159/000341589 Fig. 4. A subject showing high ALT and bilirubin. © 2012 S. Karger AG, Basel
An Integrated Analysis of Liver Safety Data from Orlistat Clinical Trials Obes Facts 2012;5:485–494 - DOI:10.1159/000341589 Fig. 5. K-M estimates of difference in treatment-emergent LFT signals between orlistat (60 and 120 mg combined) and placebo. Note: Vertical line represents error bar (± standard error). © 2012 S. Karger AG, Basel